This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Rogers BB , Zawislak C , Wong V
Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
J Adv Pract Oncol. 2021 May;12(4) :392-404
PMID: 34123476 URL: https://www.ncbi.nlm.nih.gov/pubmed/34123476
AbstractImmune checkpoint inhibitors target suppressor receptors, including cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1). The activated T cells are not antigen specific; therefore, the blockade of the immune checkpoint may result in the development of autoimmune adverse events. The most common immune-related adverse events (irAEs) are rash, colitis, and endocrinopathies. However, irAEs that affect the hematologic system are rare and can affect red blood cells (e.g., autoimmune hemolytic anemia), white blood cells, and platelets (e.g., immune thrombocytopenia). Usually one cell line is affected; however, in some cases, multiple cell lines can be affected. Other changes in the hematologic system can also be affected (e.g., cryoglobulinemia, cytokine release syndrome). Due to the rarity and lack of recognition of these AEs, the timing, spectrum of events, and clinical presentation are poorly understood. Management of hematologic irAEs usually involves the use of steroids; however, other agents (e.g., IVIG, cyclosporine, rituximab) or procedures (e.g., plasma exchange, transfusions) can also be used.
Notes2150-0886 Rogers, Barbara Barnes Zawislak, Carolyn Wong, Victoria Journal Article J Adv Pract Oncol. 2021 May;12(4):392-404. doi: 10.6004/jadpro.2021.12.4.4. Epub 2021 May 1.